
Benefits of Treating Hemophilia with Factor Concentrate
Also Available In: Japanese Treating people with hemophilia with safe, regulated plasma-derived factor concentrate directly reduces the social and economic
Year: 2025
Language: English
Author(s): World Federation of Hemophilia
Format: Video
The World Federation of Hemophilia invited representatives from its national member organizations, national governments, healthcare providers, industry partners, and other patient advocacy and scientific organizations from the global bleeding disorders community to an informational webinar on the recent milestone revisions to the World Health Organization (WHO) Essential Medicines List (EML). The objectives of this webinar were to provide information on these critical changes to WHO EML brining it more up-to-date with the international clinical guidelines for hemophilia and von Willebrand Disease, the advocacy carried out by the WFH in collaboration with key partners and stakeholders from the bleeding disorders community, and what does this mean in practice for our community. During the webinar participants heard from WFH President, Cesar Garrido, WFH Vice President Medical, Glenn Pierce, MD, PhD and Brian O’Mahony, Chief Executive, Irish Haemophilia Society, followed by a Q&A session.
Date recorded: October 17th, 2025.
The WFH does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals. For diagnosis or consultation on a specific medical problem, the WFH recommends that you contact your physician or local treatment centre. Before administering any products, the WFH urges patients to check dosages with a physician or hemophilia centre staff, and to consult the pharmaceutical company’s printed instructions.
The WFH does not promote any particular pharmaceutical product and any mention of any commercial brand in this presentation is strictly for educational purposes.

Also Available In: Japanese Treating people with hemophilia with safe, regulated plasma-derived factor concentrate directly reduces the social and economic

Also Available In: Japanese This fact sheet demonstrates the benefits of providing basic treatment and care to people with hemophilia.

In this monograph, the author offers his perspective on the risk of infection from recombinant and plasma-derived products.

This resource has also been translated into the following languages, with permission from the WFH, by NMOs: Russian A multifaceted

Small pool heat-treated intermediate purity concentrate may be the most suitable and cost-effective solution for some countries attempting sufficiency and

This monograph provides guidelines for the production of single-donor cryoprecipitate.